TARRYTOWN, N.Y., Dec. 19,
2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) will webcast its presentation at the 41st
Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023. The presentation is
scheduled for 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) and may be accessed from
the "Investors & Media" page of Regeneron's website at
http://investor.regeneron.com/events-and-presentations. An archived
version of the presentation will be available for at least 30
days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that
invents, develops and commercializes life-transforming medicines
for people with serious diseases. Founded and led for nearly 35
years by physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to nine
FDA-approved treatments and product candidates in development,
almost all of which were homegrown in our laboratories. Our
medicines and pipeline are designed to help patients with eye
diseases, allergic and inflammatory diseases, cancer,
cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary VelociSuite®
technologies, such as VelocImmune®, which uses unique
genetically humanized mice to produce optimized fully human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For more information, please visit www.Regeneron.com or
follow @Regeneron on Twitter.
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com
View original
content:https://www.prnewswire.com/news-releases/regeneron-announces-presentation-at-the-41st-annual-jp-morgan-healthcare-conference-301704024.html
SOURCE Regeneron Pharmaceuticals, Inc.